133 related articles for article (PubMed ID: 16112862)
1. Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency.
Bogen S; Saksena AK; Arasappan A; Gu H; Njoroge FG; Girijavallabhan V; Pichardo J; Butkiewicz N; Prongay A; Madison V
Bioorg Med Chem Lett; 2005 Oct; 15(20):4515-9. PubMed ID: 16112862
[TBL] [Abstract][Full Text] [Related]
2. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
Bogen SL; Ruan S; Liu R; Agrawal S; Pichardo J; Prongay A; Baroudy B; Saksena AK; Girijavallabhan V; Njoroge FG
Bioorg Med Chem Lett; 2006 Mar; 16(6):1621-7. PubMed ID: 16387495
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
[TBL] [Abstract][Full Text] [Related]
4. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
Arasappan A; Njoroge FG; Chen KX; Venkatraman S; Parekh TN; Gu H; Pichardo J; Butkiewicz N; Prongay A; Madison V; Girijavallabhan V
Bioorg Med Chem Lett; 2006 Aug; 16(15):3960-5. PubMed ID: 16730985
[TBL] [Abstract][Full Text] [Related]
5. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105
[TBL] [Abstract][Full Text] [Related]
6. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
Bogen SL; Arasappan A; Velazquez F; Blackman M; Huelgas R; Pan W; Siegel E; Nair LG; Venkatraman S; Guo Z; Doll R; Shih NY; Njoroge FG
Bioorg Med Chem; 2010 Mar; 18(5):1854-65. PubMed ID: 20149666
[TBL] [Abstract][Full Text] [Related]
8. Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.
Chen KX; Vibulbhan B; Yang W; Cheng KC; Liu R; Pichardo J; Butkiewicz N; Njoroge FG
Bioorg Med Chem; 2008 Feb; 16(4):1874-83. PubMed ID: 18032054
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V
J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623
[TBL] [Abstract][Full Text] [Related]
13. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V
Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
15. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
16. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
Hamill P; Jean F
Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
[TBL] [Abstract][Full Text] [Related]
19. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
White PW; Llinas-Brunet M; Bös M
Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
[No Abstract] [Full Text] [Related]
20. SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease.
Malancona S; Colarusso S; Ontoria JM; Marchetti A; Poma M; Stansfield I; Laufer R; Di Marco A; Taliani M; Verdirame M; Gonzalez-Paz O; Matassa VG; Narjes F
Bioorg Med Chem Lett; 2004 Sep; 14(17):4575-9. PubMed ID: 15357995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
